Docetaxel - Starpharma

Drug Profile

Docetaxel - Starpharma

Alternative Names: Dendrimer docetaxel; DEP™-Docetaxel; DTX-SPL8783

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Starpharma
  • Developer Monash University; Starpharma
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Australia (IV, Infusion)
  • 28 Nov 2017 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy) in United Kingdom (IV) (EudraCT2016-000877-19)
  • 28 Nov 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Monotherapy) in United Kingdom (IV) (EudraCT2016-000877-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top